Mass-Spec Dx Makers Should Look To FDA's Multiplex, Multivariate Approach For Regulatory Tips
This article was originally published in The Gray Sheet
Executive Summary
As FDA develops a framework for liquid chromatography-mass spectrometry diagnostics, the agency's previously circulated policies on multiplex test instrument systems and in vitro diagnostic multivariate index assays offer hints as to what LC-MS companies can expect.